Trial Profile
The noninterventional study of cabazitaxel patients with metastatic castration resistant prostate cancer (mCRPC): QoLiTime
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 25 Oct 2018
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary) ; Prednisolone (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms QoLiTime
- 12 Sep 2016 Results published in the BJU International
- 14 Dec 2015 New trial record